A comparative study of reduced dose alemtuzumab in matched unrelated donor and related donor reduced intensity transplants

In vivo T cell depletion with 100 mg alemtuzumab prevents graft‐versus‐host disease (GVHD) in reduced intensity conditioned transplants but is associated with delayed immune reconstitution, a higher risk of infection and relapse. De‐escalation studies have shown that a reduced dose of 30 mg is as ef...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Br J Haematol
Egile Nagusiak: Jardine, Laura, Publicover, Amy, Bigley, Venetia, Hale, Geoff, Pearce, Kim, Dickinson, Anne, Jackson, Graham, Collin, Matthew
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2015
Gaiak:
Transplantation
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4737113/
https://ncbi.nlm.nih.gov/pubmed/25640315
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.13239
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak